Pharmacogenetics of drug-induced birth defects: What is known so far?Wilffert, B., Altena, J., Tijink, L., van Gelder, M. M. H. J. & de Jong-van den Berg, L. T. W., Apr-2011, In : Pharmacogenomics. 12, 4, p. 547-558 12 p.
Research output: Contribution to journal › Review article › Academic › peer-review
A literature review was performed to collect information on the role of pharmacogenetics in six proposed teratogenic mechanisms associated with drug use during pregnancy: folate antagonism, oxidative stress, angiotensin-converting enzyme inhibition and angiotensin II receptor antagonism, cyclooxygenase-1 and -2 inhibition, 5-hydroxytryptamine-reuptake inhibition and drug transporters in the placenta. Data on the direct relationship between pharmacogenetics and drug-induced birth defects were found for folate metabolism, oxidative stress caused by phenytoin exposure and drug transporters in the placenta. Although no specific data to support pharmacogenetic-related birth defects were found for the NSAIDs, paroxetine and fluoxetine, it might be expected that polymorphisms modify their teratogenic effects. The usually low prevalence of drug-induced malformations impedes the demonstration of the contribution of pharmacogenetics. Large-scale studies, preferably case control studies, are needed.
|Number of pages||12|
|Publication status||Published - Apr-2011|
- 5-HT-reuptake inhibition, angiotensin II receptor antagonists, angiotensin-converting enzyme inhibition, COX-1 inhibition, COX-2 inhibition, drug-induced birth defects, folate antagonism, oxidative stress, pharmacogenetics, placental drug transporters, NEURAL-TUBE DEFECTS, SEROTONIN-REUPTAKE INHIBITORS, REDUCED FOLATE CARRIER, NONSTEROIDAL ANTIINFLAMMATORY DRUGS, METHYLENETETRAHYDROFOLATE REDUCTASE MTHFR, HOMOCYSTEINE METHYLTRANSFERASE BHMT, MALFORMATIONS FOLLOWING EXPOSURE, GLUTAMATE CARBOXYPEPTIDASE-II, RECEPTOR GENE POLYMORPHISMS, CYSTATHIONINE BETA-SYNTHASE